RespiriTB

Progress new assets (one pre-new molecular entity and one first-time-in-human start) for tuberculosis that act synergistically with bedaquiline, cytochrome bc or cytochrome bd inhibitors
RespiriTB logo

FACTS & FIGURES

Start Date
End Date
Call
IMI2 - Call 16
Grant agreement number
853903

Type of Action: 
RIA (Research and Innovation Action)

Contributions
IMI Funding
6 840 000
EFPIA in kind
3 122 900
Total Cost
9 962 900

Summary

In 2017, an estimated 558 000 new cases of drug-resistant tuberculosis (TB) were diagnosed; most of these (82 %) were multidrug-resistant (MDR), meaning they are resistant to at least two of the most effective, front line antibiotics used to treat TB. MDR-TB is extremely difficult to treat; a full course of antibiotics can last up to two years, and trigger unpleasant side effects. Moreover, the drugs used are expensive, and are not always available. The goal of RespiriTB is to advance the development of new drug candidates that could be part of a new, more effective, shorter regimen to treat MDR-TB. The team is particularly interested in compounds that interfere with the TB bacterial energy metabolism. The project will carry out a range of studies on the drug candidates selected, including initial clinical studies in humans. Ultimately, the project hopes to contribute to the development of a new, more efficient combination drug regimen for MDR-TB, with a shorter treatment duration and a lower risk of further drug resistance.

RespiriTB is part of the IMI AMR Accelerator Programme.

Participants Show participants on map

EFPIA companies
  • Janssen Pharmaceutica Nv, Beerse, Belgium
Universities, research organisations, public bodies, non-profit groups
  • Academisch Ziekenhuis Leiden, Leiden, Netherlands
  • Kobenhavns Universitet, Copenhagen, Denmark
  • Medizinische Universitaet Wien, Vienna, Austria
  • Sorbonne Universite, Paris, France
  • Universiteit Antwerpen, Antwerp, Belgium
  • Universiteit Leiden, Leiden, Netherlands
Small and medium-sized enterprises (SMEs) and mid-sized companies (<€500 m turnover)
  • Ffund BV, Amsterdam, Netherlands
  • Mitologics, Romainville, France

CONTACT

Project coordinator
Meindert H. Lamers
ACADEMISCH ZIEKENHUIS LEIDEN
m.h.lamers[at]lumc.nl